Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria.

Published byAnke van der Velde Modified over 5 years ago

Similar presentations

Presentation on theme: "(A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria."— Presentation transcript:

1 (A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria (C) at baseline. (A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria (C) at baseline. R, randomization; Per-Ind, perindopril-indapamide treatment group. Bastiaan E. de Galan et al. JASN 2009;20: ©2009 by American Society of Nephrology

Download ppt "(A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria."

Similar presentations

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.
Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:2123-2133.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:
Patient disposition for the double-blind study period.

Patient disposition for the double-blind study period.
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.

Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.
Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];

Relationship between SBP levels and the urinary excretion of TNF-α (A), RANTES (B), and thiobarbituric acid–reacting substances (malondialdehyde [MDA];
Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase.

Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase.
Missense mutations in TNXB as a cause of VUR

Missense mutations in TNXB as a cause of VUR
Studies reporting the incident rate for ischemic steal syndrome per 1000 patient days. Studies reporting the incident rate for ischemic steal syndrome.

Studies reporting the incident rate for ischemic steal syndrome per 1000 patient days. Studies reporting the incident rate for ischemic steal syndrome.
Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.

Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.
Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF
Pedigrees of the families of patients 1 and 2 show that the clinical phenotype co-segregates with compound heterozygous CLDN10 variants. Pedigrees of the.

Pedigrees of the families of patients 1 and 2 show that the clinical phenotype co-segregates with compound heterozygous CLDN10 variants. Pedigrees of the.
Both patient 1 and her family members showed a normal physiological AQP2 response to DDAVP. Immunoblotting for AQP2 was performed on urinary exosomes derived.

Both patient 1 and her family members showed a normal physiological AQP2 response to DDAVP. Immunoblotting for AQP2 was performed on urinary exosomes derived.
Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.

Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.
Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.

Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.
TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.
T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.
Studies reporting the incident rate for all types of infections per 1000 patient days. Studies reporting the incident rate for all types of infections.

Studies reporting the incident rate for all types of infections per 1000 patient days. Studies reporting the incident rate for all types of infections.

Similar presentations

Ads by Google